Razelle Kurzrock
University of California, San Diego
Publications 1226
Purpose: Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the maximum tolerated dose (MTD) of tepotinib to determine the recommended phase II dose (RP2D). Experimental Design: Patients received tepotinib orally according to one of three dose‑escalation regimens (R) on a 21-day cycle: R1, 30-400 mg once daily for 14 days; R2, 30-315 mg once daily 3 x /week; or R3, 300-1400 mg once daily. After two cycles, treatment could continue in patien...
BACKGROUND:Fusions are increasingly pursued as oncology therapeutic targets. The current study evaluated differences in outcomes for fusion versus nonfusion targets. METHODS:Outcomes were compared for patients with fusions versus those with other alterations for US Food and Drug Administration-approved single agents (from package inserts) and for patients treated at the University of California at San Diego. RESULTS:A total of 28 drugs approved by the US Food and Drug Administration (6189 patien...
#1Jacob J. Adashek (USF: University of South Florida)
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 4 authors...
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to, increased expression of the CTLA-4 and PD-1 checkpoints on their CD4+ T cells. Even so, HIV-positive patients are generally excluded from immunotherapy cancer clinical trials due to safety concerns. Hence, only case series have been published rega...
#1Sarabjot PablaH-Index: 3
#2Jeffrey ConroyH-Index: 24
Last.Carl MorrisonH-Index: 54
view all 46 authors...
Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity to ICIs in non-small cell lung cancer (NSCLC) patients. Tumor specimens from 120 NSCLC patients from 10 institutions were evaluated for PD-L1 expression by immunohistochemistry, and global proliferative profile by targeted RNA-seq. Cell pr...
4 CitationsSource
Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies. Herein, we investigated the clinical utility of circulating tumor DNA (ctDNA) (the liquid biopsy) in this malignancy.
Author(s): Adashek, Jacob J; Kato, Shumei; Ferrara, Roberto; Lo Russo, Giuseppe; Kurzrock, Razelle | Abstract: There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a minority subgroup treated with ICIs who demonstrate a paradoxical acceleration in the rate...
Introduction/Background With advances in precision cancer medicine, personalized therapy approaches based on ‘omic’ analyses are being investigated. We present a patient with treatment refractory, metastatic ovarian cancer who achieved dramatic tumor reduction with a combination matched targeted therapy approach. Methodology Genomic aberrations were assessed using next-generation sequencing (NGS) from formalin-fixed paraffin embedded surgical tumor tissue (315 genes) (Foundation Medicine). Estro...